{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:37:21Z","timestamp":1780925841671,"version":"3.54.1"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"D1","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Z01 BC006150"],"award-info":[{"award-number":["Z01 BC006150"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIC BC011475"],"award-info":[{"award-number":["ZIC BC011475"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC010411"],"award-info":[{"award-number":["ZIA BC010411"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIC BC011509"],"award-info":[{"award-number":["ZIC BC011509"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P41 GM103504"],"award-info":[{"award-number":["P41 GM103504"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CellMiner Cross-Database (CellMinerCDB, discover.nci.nih.gov\/cellminercdb) allows integration and analysis of molecular and pharmacological data within and across cancer cell line datasets from the National Cancer Institute (NCI), Broad Institute, Sanger\/MGH and MD Anderson Cancer Center (MDACC). We present CellMinerCDB 1.2 with updates to datasets from NCI-60, Broad Cancer Cell Line Encyclopedia and Sanger\/MGH, and the addition of new datasets, including NCI-ALMANAC drug combination, MDACC Cell Line Project proteomic, NCI-SCLC DNA copy number and methylation data, and Broad methylation, genetic dependency and metabolomic datasets. CellMinerCDB (v1.2) includes several improvements over the previously published version: (i) new and updated datasets; (ii) support for pattern comparisons and multivariate analyses across data sources; (iii) updated annotations with drug mechanism of action information and biologically relevant multigene signatures; (iv) analysis speedups via caching; (v) a new dataset download feature; (vi) improved visualization of subsets of multiple tissue types; (vii) breakdown of univariate associations by tissue type; and (viii) enhanced help information. The curation and common annotations (e.g. tissues of origin and identifiers) provided here across pharmacogenomic datasets increase the utility of the individual datasets to address multiple researcher question types, including data reproducibility, biomarker discovery and multivariate analysis of drug activity.<\/jats:p>","DOI":"10.1093\/nar\/gkaa968","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T19:14:54Z","timestamp":1603134894000},"page":"D1083-D1093","source":"Crossref","is-referenced-by-count":184,"title":["CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-371X","authenticated-orcid":false,"given":"Augustin","family":"Luna","sequence":"first","affiliation":[{"name":"cBio Center, Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston,\u00a0MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathi","family":"Elloumi","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda,\u00a0MD 20892, USA"},{"name":"General Dynamics Information Technology Inc., Fairfax, VA\u00a022042, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Varma","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda,\u00a0MD 20892, USA"},{"name":"HiThru Analytics LLC, Princeton, NJ 08540,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghsin","family":"Wang","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda,\u00a0MD 20892, USA"},{"name":"General Dynamics Information Technology Inc., Fairfax, VA\u00a022042, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinodh\u00a0N","family":"Rajapakse","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda,\u00a0MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirit I","family":"Aladjem","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda,\u00a0MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Robert","sequence":"additional","affiliation":[{"name":"Inserm unit\u00e9 1218, Universit\u00e9 de Bordeaux, Bordeaux 33076,\u00a0France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Sander","sequence":"additional","affiliation":[{"name":"cBio Center, Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston,\u00a0MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Pommier","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda,\u00a0MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Reinhold","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda,\u00a0MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"2021010313135030200_B1","doi-asserted-by":"crossref","first-page":"140035","DOI":"10.1038\/sdata.2014.35","article-title":"Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies","volume":"1","author":"Cowley","year":"2014","journal-title":"Sci. Data"},{"key":"2021010313135030200_B2","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-12-3342","article-title":"The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology","volume":"73","author":"Abaan","year":"2013","journal-title":"Cancer Res."},{"key":"2021010313135030200_B3","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","article-title":"CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set","volume":"72","author":"Reinhold","year":"2012","journal-title":"Cancer Res."},{"key":"2021010313135030200_B4","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-15-0335","article-title":"Using CellMiner 1.6 for systems pharmacology and genomic analysis of the NCI-60","volume":"21","author":"Reinhold","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"2021010313135030200_B5","doi-asserted-by":"crossref","first-page":"e101670","DOI":"10.1371\/journal.pone.0101670","article-title":"NCI-60 whole exome sequencing and pharmacological CellMiner analyses","volume":"9","author":"Reinhold","year":"2014","journal-title":"PLoS One"},{"key":"2021010313135030200_B6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/0008-5472.CAN-16-0655","article-title":"The NCI-60 methylome and its integration into CellMiner","volume":"77","author":"Reinhold","year":"2017","journal-title":"Cancer Res."},{"key":"2021010313135030200_B7","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021010313135030200_B8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature"},{"key":"2021010313135030200_B9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"2021010313135030200_B10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2021010313135030200_B11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nchembio.1986","article-title":"Correlating chemical sensitivity and basal gene expression reveals mechanism of action","volume":"12","author":"Rees","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"2021010313135030200_B12","first-page":"1035","article-title":"Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen","volume":"12","author":"Stinson","year":"1992","journal-title":"Anticancer Res."},{"key":"2021010313135030200_B13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1126\/science.1411538","article-title":"Neural computing in cancer drug development: predicting mechanism of action","volume":"258","author":"Weinstein","year":"1992","journal-title":"Science"},{"key":"2021010313135030200_B14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1126\/science.275.5298.343","article-title":"An information-intensive approach to the molecular pharmacology of cancer","volume":"275","author":"Weinstein","year":"1997","journal-title":"Science"},{"key":"2021010313135030200_B15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/73439","article-title":"A gene expression database for the molecular pharmacology of cancer","volume":"24","author":"Scherf","year":"2000","journal-title":"Nat. Genet."},{"key":"2021010313135030200_B16","doi-asserted-by":"crossref","first-page":"14229","DOI":"10.1073\/pnas.2331323100","article-title":"Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays","volume":"100","author":"Nishizuka","year":"2003","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021010313135030200_B17","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.isci.2019.10.059","article-title":"Quantitative proteome landscape of the NCI-60 cancer cell lines","volume":"21","author":"Guo","year":"2019","journal-title":"iScience"},{"key":"2021010313135030200_B18","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-09-3528","article-title":"Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron","volume":"70","author":"Reinhold","year":"2010","journal-title":"Cancer Res."},{"key":"2021010313135030200_B19","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1158\/1535-7163.MCT-09-0965","article-title":"mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities","volume":"9","author":"Liu","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"2021010313135030200_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-09-0321","article-title":"Multifactorial regulation of E-cadherin expression: an integrative study","volume":"9","author":"Reinhold","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"2021010313135030200_B21","doi-asserted-by":"crossref","first-page":"e92047","DOI":"10.1371\/journal.pone.0092047","article-title":"High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner","volume":"9","author":"Varma","year":"2014","journal-title":"PLoS One"},{"key":"2021010313135030200_B22","doi-asserted-by":"crossref","first-page":"e0171582","DOI":"10.1371\/journal.pone.0171582","article-title":"Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay","volume":"12","author":"Ji","year":"2017","journal-title":"PLoS One"},{"key":"2021010313135030200_B23","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1158\/0008-5472.CAN-18-2047","article-title":"RNA sequencing of the NCI-60: integration into CellMiner and CellMinerCDB","volume":"79","author":"Reinhold","year":"2019","journal-title":"Cancer Res."},{"key":"2021010313135030200_B24","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1158\/1535-7163.MCT-10-0674","article-title":"Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10]with fluorouracil, floxuridine, and topoisomerase 1 poisons","volume":"9","author":"Gmeiner","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"2021010313135030200_B25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature03664","article-title":"Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma","volume":"436","author":"Garraway","year":"2005","journal-title":"Nature"},{"key":"2021010313135030200_B26","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41591-019-0404-8","article-title":"The landscape of cancer cell line metabolism","volume":"25","author":"Li","year":"2019","journal-title":"Nat. Med."},{"key":"2021010313135030200_B27","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR\u2013Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat. Genet."},{"key":"2021010313135030200_B28","doi-asserted-by":"crossref","first-page":"564.e16","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"2021010313135030200_B29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"2021010313135030200_B30","doi-asserted-by":"crossref","first-page":"387.e16","DOI":"10.1016\/j.cell.2019.12.023","article-title":"Quantitative proteomics of the Cancer Cell Line Encyclopedia","volume":"180","author":"Nusinow","year":"2020","journal-title":"Cell"},{"key":"2021010313135030200_B31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.isci.2018.11.029","article-title":"CellMinerCDB for integrative cross-database genomics and pharmacogenomics analyses of cancer cell lines","volume":"10","author":"Rajapakse","year":"2018","journal-title":"iScience"},{"key":"2021010313135030200_B32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature15736","article-title":"Pharmacogenomic agreement between two cancer cell line data sets","volume":"528","author":"Cancer Cell Line Encyclopedia Consortium and Genomics of Drug Sensitivity in Cancer Consortium","year":"2015","journal-title":"Nature"},{"key":"2021010313135030200_B33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"2021010313135030200_B34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2017-03-735654","article-title":"The NCI Genomic Data Commons as an engine for precision medicine","volume":"130","author":"Jensen","year":"2017","journal-title":"Blood"},{"key":"2021010313135030200_B35","doi-asserted-by":"crossref","first-page":"D994","DOI":"10.1093\/nar\/gkx911","article-title":"PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies","volume":"46","author":"Smirnov","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2021010313135030200_B36","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"2021010313135030200_B37","doi-asserted-by":"crossref","first-page":"W148","DOI":"10.1093\/nar\/gky434","article-title":"GDA, a web-based tool for genomics and drugs integrated analysis","volume":"46","author":"Caroli","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2021010313135030200_B38","doi-asserted-by":"crossref","first-page":"1437.e17","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"2021010313135030200_B39","doi-asserted-by":"crossref","first-page":"D960","DOI":"10.1093\/nar\/gkq910","article-title":"CancerResource: a comprehensive database of cancer-relevant proteins and compound interactions supported by experimental knowledge","volume":"39","author":"Ahmed","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"2021010313135030200_B40","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/bioinformatics\/btx744","article-title":"GDSCTools for mining pharmacogenomic interactions in cancer","volume":"34","author":"Cokelaer","year":"2018","journal-title":"Bioinformatics"},{"key":"2021010313135030200_B41","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/bioinformatics\/btv723","article-title":"PharmacoGx: an R package for analysis of large pharmacogenomic datasets","volume":"32","author":"Smirnov","year":"2016","journal-title":"Bioinformatics"},{"key":"2021010313135030200_B42","doi-asserted-by":"crossref","first-page":"W43","DOI":"10.1093\/nar\/gkz337","article-title":"DrugComb: an integrative cancer drug combination data portal","volume":"47","author":"Zagidullin","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2021010313135030200_B43","first-page":"D871","article-title":"DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy","volume":"48","author":"Liu","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"2021010313135030200_B44","doi-asserted-by":"crossref","first-page":"W494","DOI":"10.1093\/nar\/gkaa421","article-title":"SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology","volume":"48","author":"Seo","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"2021010313135030200_B45","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1038\/s41467-020-16589-8","article-title":"BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice","volume":"11","author":"Perkail","year":"2020","journal-title":"Nat. Commun."},{"key":"2021010313135030200_B46","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/genes10100766","article-title":"Integration of bioinformatics resources reveals the therapeutic benefits of gemcitabine and cell cycle intervention in SMAD4-deleted pancreatic ductal adenocarcinoma","volume":"10","author":"Hsieh","year":"2019","journal-title":"Genes"},{"key":"2021010313135030200_B47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41420-020-0272-5","article-title":"Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells","volume":"6","author":"Cheteh","year":"2020","journal-title":"Cell Death Discov."},{"key":"2021010313135030200_B48","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.4049\/jimmunol.1900475","article-title":"Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC class I antigen presentation and increased PD-L1 expression","volume":"203","author":"Kriegsman","year":"2019","journal-title":"J. Immunol."},{"key":"2021010313135030200_B49","doi-asserted-by":"crossref","first-page":"108296","DOI":"10.1016\/j.celrep.2020.108296","article-title":"SCLC_CellMiner: integrated genomics and therapeutics predictors of small cell lung cancer cell lines based on their genomic signatures","volume":"33","author":"Tlemsani","year":"2020","journal-title":"Cell Rep."},{"key":"2021010313135030200_B50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fchem.2019.00509","article-title":"Predicting synergism of cancer drug combinations using NCI-ALMANAC data","volume":"7","author":"Sidorov","year":"2019","journal-title":"Front. Chem."},{"key":"2021010313135030200_B51","doi-asserted-by":"crossref","first-page":"djw122","DOI":"10.1093\/jnci\/djw122","article-title":"Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression","volume":"108","author":"Polley","year":"2016","journal-title":"J. Natl Cancer Inst."},{"key":"2021010313135030200_B52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13148-020-00876-8","article-title":"Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets","volume":"12","author":"Krushkal","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"2021010313135030200_B53","doi-asserted-by":"crossref","first-page":"e99269","DOI":"10.1371\/journal.pone.0099269","article-title":"Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype","volume":"9","author":"Kohn","year":"2014","journal-title":"PLoS One"},{"key":"2021010313135030200_B54","doi-asserted-by":"crossref","first-page":"e49020","DOI":"10.7554\/eLife.49020","article-title":"Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction","volume":"8","author":"Wang","year":"2019","journal-title":"eLife"},{"key":"2021010313135030200_B55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/tlcr.2018.02.02","article-title":"Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes","volume":"7","author":"Zhang","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"2021010313135030200_B56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","article-title":"The Cellosaurus, a cell-line knowledge resource","volume":"29","author":"Bairoch","year":"2018","journal-title":"J. Biomol. Tech."},{"key":"2021010313135030200_B57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"2021010313135030200_B58","doi-asserted-by":"crossref","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","article-title":"PubChem substance and compound databases","volume":"44","author":"Kim","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2021010313135030200_B59","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/bioinformatics\/btv701","article-title":"rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R","volume":"32","author":"Luna","year":"2016","journal-title":"Bioinformatics"},{"key":"2021010313135030200_B60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-0716-0239-3_15","article-title":"The essential toolbox of data science: Python, R, Git, and Docker","volume":"2104","author":"Pittard","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"2021010313135030200_B61","doi-asserted-by":"crossref","first-page":"l1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"2021010313135030200_B62","doi-asserted-by":"crossref","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards suite: from gene data mining to disease genome sequence analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr. Protoc. Bioinformatics"},{"key":"2021010313135030200_B63","first-page":"D489","article-title":"Pathway Commons 2019 update: integration, analysis and exploration of pathway data","volume":"48","author":"Rodchenkov","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"2021010313135030200_B64","doi-asserted-by":"crossref","first-page":"825","DOI":"10.12688\/f1000research.8705.1","article-title":"Assessment of pharmacogenomic agreement","volume":"5","author":"Safikhani","year":"2016","journal-title":"F1000Res."},{"key":"2021010313135030200_B65","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature12831","article-title":"Inconsistency in large pharmacogenomic studies","volume":"504","author":"Haibe-Kains","year":"2013","journal-title":"Nature"},{"key":"2021010313135030200_B66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"key":"2021010313135030200_B67","doi-asserted-by":"crossref","first-page":"27297","DOI":"10.1074\/jbc.M115.652339","article-title":"FACT proteins, SUPT16H and SSRP1, are transcriptional suppressors of HIV-1 and HTLV-1 that facilitate viral latency","volume":"290","author":"Huang","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2021010313135030200_B68","first-page":"393","article-title":"The role of the E-cadherin\/catenin complex in gastrointestinal cancer","volume":"62","author":"Debruyne","year":"1999","journal-title":"Acta Gastroenterol. Belg."},{"key":"2021010313135030200_B69","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the Lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"2021010313135030200_B70","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.trecan.2016.11.002","article-title":"DNA-targeted precision medicine; have we been caught sleeping?","volume":"3","author":"Reinhold","year":"2017","journal-title":"Trends Cancer Res."},{"key":"2021010313135030200_B71","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bjc.6605144","article-title":"Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer","volume":"101","author":"Doherty","year":"2009","journal-title":"Br. J. Cancer"},{"key":"2021010313135030200_B72","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ng.3812","article-title":"SMARCD2 subunit of SWI\/SNF chromatin-remodeling complexes mediates granulopoiesis through a CEBP\u03f5 dependent mechanism","volume":"49","author":"Priam","year":"2017","journal-title":"Nat. Genet."},{"key":"2021010313135030200_B73","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","volume":"201","author":"Murai","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"2021010313135030200_B74","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1038\/onc.2017.46","article-title":"Compromised BRCA1\u2013PALB2 interaction is associated with breast cancer risk","volume":"36","author":"Foo","year":"2017","journal-title":"Oncogene"},{"key":"2021010313135030200_B75","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon.12.31","article-title":"Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor","volume":"8","author":"Patrawala","year":"2012","journal-title":"Future Oncol."},{"key":"2021010313135030200_B76","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2021010313135030200_B77","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1128\/MCB.23.18.6702-6712.2003","article-title":"Targeted disruption of the inosine 5\u2032-monophosphate dehydrogenase type I gene in mice","volume":"23","author":"Gu","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"2021010313135030200_B78","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.12688\/f1000research.9611.1","article-title":"Revisiting inconsistency in large pharmacogenomic studies","volume":"5","author":"Safikhani","year":"2016","journal-title":"F1000Res."},{"key":"2021010313135030200_B79","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer"},{"key":"2021010313135030200_B80","doi-asserted-by":"crossref","first-page":"321.e10","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/49\/D1\/D1083\/35363776\/gkaa968.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/49\/D1\/D1083\/35363776\/gkaa968.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T03:18:54Z","timestamp":1723778334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/49\/D1\/D1083\/5983630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":80,"journal-issue":{"issue":"D1","published-online":{"date-parts":[[2020,11,16]]},"published-print":{"date-parts":[[2021,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkaa968","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,8]]},"published":{"date-parts":[[2020,11,16]]}}}